#1
#1 out of 2
health1d ago
A whole new way to prevent death from sepsis shows promise
- Researchers report galectin-3–targeted apheresis showing improved survival in animal models of sepsis.
- In initial human data, sepsis patients had higher galectin-3 levels that declined among survivors.
- The approach filters blood plasma through antibodies targeting galectin-3 without removing cells.
- Experts say results must be replicated by independent groups before standard use.
- Eliaz Therapeutics seeks funding for a randomized sepsis trial planned for 2027.
- Animal models included rats with surgically induced sepsis using galectin-3 apheresis.
- In a second model, galectin-3 apheresis raised survival in lipopolysaccharide-induced sepsis in pigs.
- Galectin-3 is involved in inflammation and immune regulation and may drive septic responses.
- The research builds on multiple studies linking higher galectin-3 to sepsis mortality risk.
- The study area includes China, Europe, North America, and Australia data reviewed for galectin-3 trends.
Vote 0
